Cordyceps militaris - αποτελεσματα

Ευρωπαϊκή Ένωση - Ολλανδικά - EMA (European Medicines Agency)

ryeqo

gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - leiomyoom - hypofyse en hypothalamische hormonen en analogen - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

Ευρωπαϊκή Ένωση - Ολλανδικά - EMA (European Medicines Agency)

ponvory

janssen-cilag international n.v. - ponesimod - multiple sclerose, relapsing-remitting - immunosuppressiva - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Ευρωπαϊκή Ένωση - Ολλανδικά - EMA (European Medicines Agency)

drovelis

gedeon richter plc. - drospirenone, estetrol monohydrate - contraceptives, oral - geslachtshormonen en modulatoren van het genitale systeem, - oral contraceptive.

Ευρωπαϊκή Ένωση - Ολλανδικά - EMA (European Medicines Agency)

fingolimod mylan

mylan ireland limited - fingolimod hydrochloride - multiple sclerose, relapsing-remitting - immunosuppressiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 en 5. 1)orpatients met zich snel ontwikkelende ernstige relapsing-remitting multiple sclerose gedefinieerd door 2 of meer het uitschakelen van de recidieven in één jaar, en met 1 of meer gadolinium aankleurende laesies op de mri van de hersenen of een significante toename in t2-laesies belasting in vergelijking met een eerdere recente mri.

Ευρωπαϊκή Ένωση - Ολλανδικά - EMA (European Medicines Agency)

cibinqo

pfizer europe ma eeig - abrocitinib - dermatitis, atopic - andere dermatologische preparaten - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.